As we highlighted in prior sections, patient selection using platinum-sensitivity plus BRCA or PALB2 mutation status identifies a subset of patients with pancreatic cancer who benefit from PARPi maintenance [58,59]. This evidence concerns the gene PALB2 and pancreatic neoplasm.